FDA Gives Green Light to Medtronic’s Symplicity Renal Denervation System
U.S. commercialization of Medtronic’s new renal denervation system (RDN) to treat hypertension will begin immediately, the company announced last Friday after receiving FDA approval on the procedure known as Symplicity.
The minimally invasive procedure uses radiofrequency energy to nerves near the kidneys that can become overactive and contribute to high blood pressure.
The thumbs-up for Ireland-based Medtronic comes only days following FDA approval of Recor’s Paradise ultrasound RDN, and just three months after an agency advisory committee failed to approve Symplicity by a narrow margin.
Read the Medtronic release here.
To read the whole story, click here to subscribe.